Circio (CRNA) Investor update summary

Technology and platform advancements

• Developed circVec, a circular RNA platform for enhanced, prolonged gene expression in gene therapy, validated across multiple tissues and delivery routes.

• Demonstrated up to 40x higher gene expression in heart and 50x in eye versus conventional mRNA-based AAV therapies, with reduced off-target liver expression and cellular stress.

• The circVec advantage is driven by higher RNA transcript levels, not increased vector copy number, supporting greater stability and specificity.

• Preclinical programs are advancing in heart, eye and CNS, with collaborations and validation in larger animal models.

ASGCT data update

• Oral and poster presentations at the ASGCT 2026 Annual Meeting in Boston, held 11–15 May, showcased the latest circVec data package.

Business development and partnerships

• Strategic collaborations in the past six months include top 5 pharma, AaviGen, Acuitas, TraffikGene and United Immunity, expanding circVec applications.

• Recent industry deals highlight commercial opportunities, with comparable transactions reaching up to $2.4 billion.

• Multiple ongoing and planned out-licensing and partnering transactions are targeted within the current cash runway.